Renal failure remains a principal cause of morbidity for patients with multiple myeloma. Once reversible factors such as hypercalcemia have been corrected, the most common cause of severe renal failure in these patients is a tubulointerstitial pathology that results from the very high circulating concentrations of monoclonal immunoglobulin free light chains. These endogenous proteins can result in isolated proximal tubule cell cytotoxicity, tubulointerstitial nephritis and cast nephropathy (myeloma kidney). Less frequently, high levels of free light chains can lead to immunoglobulin light chain amyloidosis and light chain deposition disease, although these conditions are usually associated with insidious progression of renal failure rather than acute kidney injury. Unless there is rapid intervention, progressive and irreversible damage occurs, particularly interstitial fibrosis and tubular atrophy. Despite advances in our understanding of the pathogenesis of these processes there has been a gap in translating these achievements into improved patient outcomes. The International Kidney and Monoclonal Gammopathy Research Group was formed to address this need. In this Review, we discuss the mechanisms of disease and diagnostic approaches to patients with acute kidney injury complicating multiple myeloma.
The tubulointerstitial injury, cast nephropathy, is the most common cause of severe acute kidney injury in patients with multiple myeloma
Histology findings of acute tubular necrosis and acute tubulointerstitial nephritis should raise a 'red flag' for potential injury from high levels of free light chains in patients with multiple myeloma
Standard assessment of renal histology by light microscopy, immunofluorescence and electron microscopy might require the addition of specialist techniques to detect subtle injuries in patients with a monoclonal protein
Serum immunoassays can provide a rapid alternative to urine electrophoresis for the identification of monoclonal free light chains
Early diagnosis and intervention remain key to preventing irreversible renal injuries in patients with multiple myeloma
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Peto, R. Factors of prognostic significance in myelomatosis. J. Clin. Pathol. 25, 555 (1972).
Haynes, R. J., Read, S., Collins, G. P., Darby, S. C. & Winearls, C. G. Presentation and survival of patients with severe acute kidney injury and multiple myeloma: a 20-year experience from a single centre. Nephrol. Dial. Transplant. 25, 419–426 (2010).
Bladé, J. et al. Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Arch. Intern. Med. 158, 1889–1893 (1998).
Leung, N. et al. Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains. Kidney Int. 73, 1282–1288 (2008).
Hutchison, C. A. et al. Treatment of acute renal failure secondary to multiple myeloma with chemotherapy and extended high cut-off hemodialysis. Clin. J. Am. Soc. Nephrol. 4, 745–754 (2009).
Hutchison, C. A. et al. Early reduction of serum-free light chains associates with renal recovery in myeloma kidney. J. Am. Soc. Nephrol. 22, 1129–1136 (2011).
Arimura, A., Li, M. & Batuman, V. Potential protective action of pituitary adenylate cyclase-activating polypeptide (PACAP38) on in vitro and in vivo models of myeloma kidney injury. Blood 107, 661–668 (2006).
Batuman, V., Dreisbach, A. W. & Cyran, J. Light-chain binding sites on renal brush-border membranes. Am. J. Physiol. 258, F1259–F1265 (1990).
Batuman, V. & Guan, S. Receptor-mediated endocytosis of immunoglobulin light chains by renal proximal tubule cells. Am. J. Physiol. 272, F521–F530 (1997).
Batuman, V., Guan, S., O'Donovan, R. & Puschett, J. B. Effect of myeloma light chains on phosphate and glucose transport in renal proximal tubule cells. Ren. Physiol. Biochem. 17, 294–300 (1994).
Batuman, V., Sastrasinh, M. & Sastrasinh, S. Light chain effects on alanine and glucose uptake by renal brush border membranes. Kidney Int. 30, 662–665 (1986).
Batuman, V. et al. Myeloma light chains are ligands for cubilin (gp280). Am. J. Physiol. 275, F246–F254 (1998).
Klassen, R. B., Allen, P. L., Batuman, V., Crenshaw, K. & Hammond, T. G. Light chains are a ligand for megalin. J. Appl. Physiol. 98, 257–263 (2005).
Li, M., Balamuthusamy, S., Simon, E. E. & Batuman, V. Silencing megalin and cubilin genes inhibits myeloma light chain endocytosis and ameliorates toxicity in human renal proximal tubule epithelial cells. Am. J. Physiol. Renal Physiol. 295, F82–F90 (2008).
Li, M., Hering-Smith, K. S., Simon, E. E. & Batuman, V. Myeloma light chains induce epithelial-mesenchymal transition in human renal proximal tubule epithelial cells. Nephrol. Dial. Transplant. 23, 860–870 (2008).
Pote, A., Zwizinski, C., Simon, E. E., Meleg-Smith, S. & Batuman, V. Cytotoxicity of myeloma light chains in cultured human kidney proximal tubule cells. Am. J. Kidney Dis. 36, 735–744 (2000).
Sengul, S., Zwizinski, C. & Batuman, V. Role of MAPK pathways in light chain-induced cytokine production in human proximal tubule cells. Am. J. Physiol. Renal Physiol. 284, F1245–F1254 (2003).
Sengul, S. et al. Endocytosis of light chains induces cytokines through activation of NF-κB in human proximal tubule cells. Kidney Int. 62, 1977–1988 (2002).
Sanders, P. W., Herrera, G. A., Chen, A., Booker, B. B. & Galla, J. H. Differential nephrotoxicity of low molecular weight proteins including Bence Jones proteins in the perfused rat nephron in vivo. J. Clin. Invest. 82, 2086–2096 (1988).
Sanders, P. W., Booker, B. B., Bishop, J. B. & Cheung, H. C. Mechanisms of intranephronal proteinaceous cast formation by low molecular weight proteins. J. Clin. Invest. 85, 570–576 (1990).
Sanders, P. W., Herrera, G. A., Kirk, K. A., Old, C. W. & Galla, J. H. Spectrum of glomerular and tubulointerstitial renal lesions associated with monotypical immunoglobulin light chain deposition. Lab. Invest. 64, 527–537 (1991).
Sanders, P. W. & Booker, B. B. Pathobiology of cast nephropathy from human Bence Jones proteins. J. Clin. Invest. 89, 630–639 (1992).
Huang, Z. Q., Kirk, K. A., Connelly, K. G. & Sanders, P. W. Bence Jones proteins bind to a common peptide segment of Tamm-Horsfall glycoprotein to promote heterotypic aggregation. J. Clin. Invest. 92, 2975–2983 (1993).
Sanders, P. W. & Herrera, G. A. Monoclonal immunoglobulin light chain-related renal diseases. Semin. Nephrol. 13, 324–341 (1993).
Huang, Z. Q. & Sanders, P. W. Localization of a single binding site for immunoglobulin light chains on human Tamm-Horsfall glycoprotein. J. Clin. Invest. 99, 732–736 (1997).
Ying, W. Z. & Sanders, P. W. Mapping the binding domain of immunoglobulin light chains for Tamm-Horsfall protein. Am. J. Pathol. 158, 1859–1866 (2001).
Herrera, G. A. & Sanders, P. W. Paraproteinemic renal diseases that involve the tubulo-interstitium. Contrib. Nephrol. 153, 105–115 (2007).
Wang, P. X. & Sanders, P. W. Immunoglobulin light chains generate hydrogen peroxide. J. Am. Soc. Nephrol. 18, 1239–1245 (2007).
Basnayake, K., Ying, W. Z., Wang, P. X. & Sanders, P. W. Immunoglobulin light chains activate tubular epithelial cells through redox signaling. J. Am. Soc. Nephrol. 21, 1165–1173 (2010).
Ying, W. Z., Wang, P. X., Aaron, K. J., Basnayake, K. & Sanders, P. W. Immunoglobulin light chains activate NF-κB in renal epithelial cells through a Src-dependent mechanism. Blood 117, 1301–1307 (2011).
Holland, M. D., Galla, J. H., Sanders, P. W. & Luke, R. G. Effect of urinary pH and diatrizoate on Bence Jones protein nephrotoxicity in the rat. Kidney Int. 27, 46–50 (1985).
Huang, Z. Q. & Sanders, P. W. Biochemical interaction between Tamm-Horsfall glycoprotein and Ig light chains in the pathogenesis of cast nephropathy. Lab. Invest. 73, 810–817 (1995).
Solomon, A., Weiss, D. T. & Kattine, A. A. Nephrotoxic potential of Bence Jones proteins. N. Engl. J. Med. 324, 1845–1851 (1991).
Bence Jones, H. Papers on clinical pathology. Lancet 50, 88–92 (1847).
Berggård, I. & Peterson, P. A. Polymeric forms of free normal κ and λ chains of human immunoglobulin. J. Biol. Chem. 244, 4299–4307 (1969).
Mead, G. P. et al. Serum free light chains for monitoring multiple myeloma. Br. J. Haematol. 126, 348–354 (2004).
Markowitz, G. S. Dysproteinemia and the kidney. Adv. Anat. Pathol. 11, 49–63 (2004).
Sanders, P. W., Herrera, G. A. & Galla, J. H. Human Bence Jones protein toxicity in rat proximal tubule epithelium in vivo. Kidney Int. 32, 851–861 (1987).
Galla, J. H., Herrera, G. A. & Sanders, P. W. Differential toxicity of human Bence-Jones proteins in the rat proximal convoluted tubule in vivo. Contrib. Nephrol. 68, 198–202 (1988).
Sanders, P. W., Herrera, G. A., Lott, R. L. & Galla, J. H. Morphologic alterations of the proximal tubules in light chain-related renal disease. Kidney Int. 33, 881–889 (1988).
Guan, S., el-Dahr, S., Dipp, S. & Batuman, V. Inhibition of Na-K-ATPase activity and gene expression by a myeloma light chain in proximal tubule cells. J. Investig. Med. 47, 496–501 (1999).
Batuman, V. Proximal tubular injury in myeloma. Contrib. Nephrol. 153, 87–104 (2007).
Sengul, S., Li, M. & Batuman, V. Myeloma kidney: toward its prevention—with new insights from in vitro and in vivo models of renal injury. J. Nephrol. 22, 17–28 (2009).
Khan, A. M. et al. Myeloma light chain-induced renal injury in mice. Nephron Exp. Nephrol. 116, e32–e41 (2010).
Maldonado, J. E. et al. Fanconi syndrome in adults. A manifestation of a latent form of myeloma. Am. J. Med. 58, 354–364 (1975).
Herlitz, L. C., Roglieri, J., Resta, R., Bhagat, G. & Markowitz, G. S. Light chain proximal tubulopathy. Kidney Int. 76, 792–797 (2009).
Weiss, J. H. et al. Pathophysiology of acute Bence-Jones protein nephrotoxicity in the rat. Kidney Int. 20, 198–210 (1981).
Tanner, G. A. & Knopp, L. C. Glomerular blood flow after single nephron obstruction in the rat kidney. Am. J. Physiol. 250, F77–F85 (1986).
Tanner, G. A. & Evan, A. P. Glomerular and proximal tubular morphology after single nephron obstruction. Kidney Int. 36, 1050–1060 (1989).
Start, D. A., Silva, F. G., Davis, L. D., D'Agati, V. & Pirani, C. L. Myeloma cast nephropathy: immunohistochemical and lectin studies. Mod. Pathol. 1, 336–347 (1988).
Ying, W. Z. & Sanders, P. W. Dietary salt regulates expression of Tamm-Horsfall glycoprotein in rats. Kidney Int. 54, 1150–1156 (1998).
Woodruff, R. & Sweet, B. Multiple myeloma with massive Bence Jones proteinuria and preservation of renal function. Aust. NZ J. Med. 7, 60–62 (1977).
Khamlichi, A. A. et al. Role of light chain variable region in myeloma with light chain deposition disease: evidence from an experimental model. Blood 86, 3655–3659 (1995).
Decourt, C. et al. Mutational analysis in murine models for myeloma-associated Fanconi's syndrome or cast myeloma nephropathy. Blood 94, 3559–3566 (1999).
Sirac, C. et al. Role of the monoclonal κ chain V domain and reversibility of renal damage in a transgenic model of acquired Fanconi syndrome. Blood 108, 536–543 (2006).
Myatt, E. A. et al. Pathogenic potential of human monoclonal immunoglobulin light chains: relationship of in vitro aggregation to in vivo organ deposition. Proc. Natl Acad. Sci. USA 91, 3034–3038 (1994).
Aucouturier, P. et al. Monoclonal Ig L chain and L chain V domain fragment crystallization in myeloma-associated Fanconi's syndrome. J. Immunol. 150, 3561–3568 (1993).
Rocca, A. et al. Sequences of V kappa L subgroup light chains in Fanconi's syndrome. Light chain V region gene usage restriction and peculiarities in myeloma-associated Fanconi's syndrome. J. Immunol. 155, 3245–3252 (1995).
Messiaen, T. et al. Adult Fanconi syndrome secondary to light chain gammopathy. Clinicopathologic heterogeneity and unusual features in 11 patients. Medicine (Baltimore) 79, 135–154 (2000).
Déret, S. et al. Kappa light chain-associated Fanconi's syndrome: molecular analysis of monoclonal immunoglobulin light chains from patients with and without intracellular crystals. Protein Eng. 12, 363–369 (1999).
Comenzo, R. L., Zhang, Y., Martinez, C., Osman, K. & Herrera, G. A. The tropism of organ involvement in primary systemic amyloidosis: contributions of Ig VL germ line gene use and clonal plasma cell burden. Blood 98, 714–720 (2001).
Denoroy, L., Déret, S. & Aucouturier, P. Overrepresentation of the V kappa IV subgroup in light chain deposition disease. Immunol. Lett. 42, 63–66 (1994).
Cogné, M., Preud'homme, J. L., Bauwens, M., Touchard, G. & Aucouturier, P. Structure of a monoclonal kappa chain of the V kappa IV subgroup in the kidney and plasma cells in light chain deposition disease. J. Clin. Invest. 87, 2186–2190 (1991).
Stevens, F. J. Four structural risk factors identify most fibril-forming kappa light chains. Amyloid 7, 200–211 (2000).
Enqvist, S., Sletten, K., Stevens, F. J., Hellman, U. & Westermark, P. Germ line origin and somatic mutations determine the target tissues in systemic AL-amyloidosis. PLoS ONE 2, e981 (2007).
Déret, S. et al. Molecular modeling of immunoglobulin light chains implicates hydrophobic residues in non-amyloid light chain deposition disease. Protein Eng. 10, 1191–1197 (1997).
del Pozo Yauner, L. et al. Influence of the germline sequence on the thermodynamic stability and fibrillogenicity of human lambda 6 light chains. Proteins 72, 684–692 (2008).
Stevens, P. W. et al. Recombinant immunoglobulin variable domains generated from synthetic genes provide a system for in vitro characterization of light-chain amyloid proteins. Protein Sci. 4, 421–432 (1995).
Kaplan, B. et al. Free light chains in plasma of patients with light chain amyloidosis and non-amyloid light chain deposition disease. High proportion and heterogeneity of disulfide-linked monoclonal free light chains as pathogenic features of amyloid disease. Br. J. Haematol. 144, 705–715 (2009).
Kaplan, B., Livneh, A. & Gallo, G. Charge differences between in vivo deposits in immunoglobulin light chain amyloidosis and non-amyloid light chain deposition disease. Br. J. Haematol. 136, 723–728 (2007).
Klimtchuk, E. S. et al. The critical role of the constant region in thermal stability and aggregation of amyloidogenic immunoglobulin light chain. Biochemistry 49, 9848–9857 (2010).
Yamamoto, K. et al. The amyloid fibrils of the constant domain of immunoglobulin light chain. FEBS Lett. 584, 3348–3353 (2010).
Keeling, J., Teng, J. & Herrera, G. A. AL-amyloidosis and light-chain deposition disease light chains induce divergent phenotypic transformations of human mesangial cells. Lab. Invest. 84, 1322–1338 (2004).
Basnayake, K. et al. Differential progression of renal scarring and determinants of late renal recovery in sustained dialysis dependent acute kidney injury secondary to myeloma kidney. J. Clin. Pathol. 63, 884–887 (2010).
Bradwell, A. R. et al. Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clin. Chem. 47, 673–680 (2001).
Hutchison, C. A. et al. Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure. BMC Nephrol. 9, 11 (2008).
Katzmann, J. A. et al. Serum reference intervals and diagnostic ranges for free κ and free λ immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin. Chem. 48, 1437–1444 (2002).
Hutchison, C. A., Basnayake, K. & Cockwell, P. Serum free light chain assessment in monoclonal gammopathy and kidney disease. Nat. Rev. Nephrol. 5, 621–628 (2009).
Katzmann, J. A. et al. Screening panels for detection of monoclonal gammopathies. Clin. Chem. 55, 1517–1522 (2009).
Durie, B. G. et al. on behalf of the International Myeloma Working Group. International uniform response criteria for multiple myeloma. Leukemia 20, 1467–1473 (2006).
Dispenzieri, A. et al. on behalf of the International Myeloma Working Group. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 23, 215–224 (2009).
Hutchison, C. A. et al. Quantitative assessment of serum and urinary polyclonal free light chains in patients with chronic kidney disease. Clin. J. Am. Soc. Nephrol. 3, 1684–1690 (2008).
Herrera, G. A. Renal lesions associated with plasma cell dyscrasias: practical approach to diagnosis, new concepts, and challenges. Arch. Pathol. Lab. Med. 133, 249–267 (2009).
Herrera, G. A. Renal manifestations of plasma cell dyscrasias: an appraisal from the patients' bedside to the research laboratory. Ann. Diagn. Pathol. 4, 174–200 (2000).
Korbet, S. M. & Schwartz, M. M. Multiple myeloma. J. Am. Soc. Nephrol. 17, 2533–2545 (2006).
Herrera, G. A. & Picken, M. M. in Heptinstall's Pathology of the Kidney (eds Jennette, J. C., Olson, J. L. & Schwartz, M. M.) 853–910 (Lippincott-Raven, Philadelphia, 2006).
Herrera, G. A. in Silva's Diagnostic Renal Pathology (eds Zhou, X. J., Laszik, Z., Nadasdy, T., D'Agati, V. D. & Silva, F.) 345–406 (Cambridge University Press, Cambridge, 2009).
Kapur, U., Barton, K., Fresco, R., Leehey, D. J. & Picken, M. M. Expanding the pathologic spectrum of immunoglobulin light chain proximal tubulopathy. Arch. Pathol. Lab. Med. 131, 1368–1372 (2007).
Leung, N. et al. Long-term outcome of renal transplantation in light-chain deposition disease. Am. J. Kidney Dis. 43, 147–153 (2004).
Short, A. K., O'Donoghue, D. J., Riad, H. N., Short, C. D. & Roberts, I. S. Recurrence of light chain nephropathy in a renal allograft. A case report and review of the literature. Am. J. Nephrol. 21, 237–240 (2001).
Gu, X. & Herrera, G. A. Light-chain-mediated acute tubular interstitial nephritis: a poorly recognized pattern of renal disease in patients with plasma cell dyscrasia. Arch. Pathol. Lab. Med. 130, 165–169 (2006).
Isaac, J. & Herrera, G. A. Cast nephropathy in a case of Waldenström's macroglobulinemia. Nephron 91, 512–515 (2002).
Herrera, G. A. The contributions of electron microscopy to the understanding and diagnosis of plasma cell dyscrasia-related renal lesions. Med. Electron Microsc. 34, 1–18 (2001).
Herrera, G. A. & Turbat-Herrera, E. A. Ultrastructural immunolabeling in the diagnosis of monoclonal light-and heavy-chain-related renal diseases. Ultrastruct. Pathol. 34, 161–173 (2010).
Picken, M. M. & Herrera, G. A. The burden of “sticky” amyloid: typing challenges. Arch. Pathol. Lab. Med. 131, 850–851 (2007).
Sethi, S. et al. Mass spectrometry-based proteomic diagnosis of renal immunoglobulin heavy chain amyloidosis. Clin. J. Am. Soc. Nephrol. 5, 2180–2187 (2010).
Montseny, J. J. et al. Long-term outcome according to renal histological lesions in 118 patients with monoclonal gammopathies. Nephrol. Dial. Transplant. 13, 1438–1445 (1998).
Komatsuda, A. et al. Disappearance of nodular mesangial lesions in a patient with light chain nephropathy after long-term chemotherapy. Am. J. Kidney Dis. 35, E9 (2000).
Hotta, O. & Taguma, Y. Resolution of nodular glomerular lesions in a patient with light-chain nephropathy. Nephron 91, 504–505 (2002).
Clark, A. D., Shetty, A. & Soutar, R. Renal failure and multiple myeloma: pathogenesis and treatment of renal failure and management of underlying myeloma. Blood Rev. 13, 79–90 (1999).
Haubitz, M. & Peest, D. Myeloma—new approaches to combined nephrological-haematological management. Nephrol. Dial. Transplant. 21, 582–590 (2006).
Penfield, J. G. Multiple myeloma in end-stage renal disease. Semin. Dial. 19, 329–334 (2006).
Mead, G. P. & Drayson, M. T. Sensitivity of serum free light chain measurement of residual disease in multiple myeloma patients. Blood 114, 1717 (2009).
Drayson, M. et al. Effects of paraprotein heavy and light chain types and free light chain load on survival in myeloma: an analysis of patients receiving conventional-dose chemotherapy in Medical Research Council UK multiple myeloma trials. Blood 108, 2013–2019 (2006).
Cockwell, P. & Hutchison, C. A. Management options for cast nephropathy in multiple myeloma. Curr. Opin. Nephrol. Hypertens. 19, 550–555 (2010).
Pratt, G. The evolving use of serum free light chain assays in haematology. Br. J. Haematol. 141, 413–422 (2008).
Elliss-Brookes, L. et al. Routes to Diagnosis: NCIN Data Briefing. National Cancer Intelligence Network [online], (2010).
The authors of this manuscript would like to thank the other members of the International Kidney and Monoclonal Gammopathy Research Group for their intellectual support in the review process for this manuscript: J. Bladé, P. Cockwell, M. Cook, M. Drayson, J.-P. Fermand, S. Kastritis, R. Kyle, N. Leung and C. Winearls. P. W. Sanders' research was supported by National Institutes of Health grant R01 DK46199 and P30 DK079337 (George M. O'Brien Kidney and Urological Research Centers Program) and the Office of Research and Development, Medical Research Service, Department of Veterans Affairs.
C. A. Hutchison has received speakers bureau honoraria and grant/research support from Binding Site. The other authors declare no competing interests.
PubMed and MEDLINE were searched using the terms “multiple myeloma”, “monoclonal protein”, “free light chain”, “acute kidney injury”, “renal/kidney impairment” and “cast nephropathy”. No language restrictions were placed on the search and all publications from 1970 to 2010 were considered.
About this article
Cite this article
Hutchison, C., Batuman, V., Behrens, J. et al. The pathogenesis and diagnosis of acute kidney injury in multiple myeloma. Nat Rev Nephrol 8, 43–51 (2012). https://doi.org/10.1038/nrneph.2011.168
Association of serum calcium levels with renal impairment and all-cause death in Chinese patients with newly diagnosed multiple myeloma: a cross-sectional, longitudinal study
Nutrition & Metabolism (2021)
Nature Reviews Nephrology (2021)
A non-invasive differential diagnostic model for light chain cast nephropathy in newly diagnosed multiple myeloma patients with renal involvement: a multicenter study
Journal of Nephrology (2021)
Blood Cancer Journal (2020)
Journal of Nephrology (2020)